Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?

Berridge C. et al, (2024), BJU Int

New role of fat-free mass in cancer risk linked with genetic predisposition.

Harris BHL. et al, (2024), Sci Rep, 14

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those withde novometastatic disease

Charlton P. et al, (2023)

Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.

Rao SR. et al, (2023), Int J Mol Sci, 24

Geometric Anatomy Basis for Safe and Effective Focal Ablation of Prostate Cancer by Irreversible Electroporation (IRE)

Cussenot O. et al, (2023), Anatomia, 2, 232 - 242

Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.

Bryant RJ. et al, (2023), BJU Int, 131, 694 - 704

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Hamdy FC. et al, (2023), N Engl J Med, 388, 1547 - 1558

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

Donovan JL. et al, (2023), NEJM Evid, 2

Same day discharge robot‐assisted laparoscopic prostatectomy ‐ feasibility, safety & patient experience

Hill GT. et al, (2023), BJU International

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features

Rao SR. et al, (2023)

The ‘Rapid Access Prostate Imaging and Diagnosis’ (RAPID) diagnostic pathway: what is the rush?

Lopez JF. and Bryant RJ., (2023), BJU International

Investigating the effects of homologous recombination deficiency on radiotherapy response in pre-clinical prostate cancer

Kwon J. et al, (2023), EUROPEAN UROLOGY, 83

Natural history of Atypical Small Acinar Proliferation (ASAP): A 10-year contemporary series

Anbarasan T. et al, (2023), EUROPEAN UROLOGY, 83, S418 - S419

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

Figiel S. et al, (2023), EUROPEAN UROLOGY, 83

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.

Sooriakumaran P. et al, (2022), BJU Int, 130, 43 - 53

‘Case of the Month’ from Oxford University Hospitals, Oxford, UK: ketamine uropathy with metallic stents and obstructing calculus

Hamilton‐Baillie A. et al, (2022), BJU International, 129, 582 - 584

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Fletcher CE. et al, (2022), Mol Cancer, 21

COVID-19 DISRUPTION TO PROSTATE CANCER MANAGEMENT IN A UK TERTIARY REFERRAL CENTRE

Byrne M. et al, (2022), JOURNAL OF UROLOGY, 207, E47 - E47

Fluorine-18 (18F) Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) and the diagnosis and staging of primary Prostate Cancer (PCa)

Byrne MHV. et al, (2022), EUROPEAN UROLOGY, 81, S1105 - S1106

Load More

1
2
3
4
5
6

Include forthcoming?